The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 5, 2011, Pages 492-499

  Shin, Kwang Hee ^a   Kim, Tae Eun ^a   Kim, Sung Eun ^a   Lee, Min Goo ^b   Song, Im Sook ^c   Yoon, Seo Hyun ^a   Cho, Joo Youn ^a   Jang, In Jin ^a   Shin, Sang Goo ^a   Yu, Kyung Sang ^a  

^a Seoul National University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Inje University   (South Korea)

Author keywords

atorvastatin; drug interaction; fimasartan; OATP1B1; pharmacokinetics

Indexed keywords

2 HYDROXY ATROVASTAIN LACTONE; 2 HYDROXYATORVASTATIN ACID; ATORVASTATIN; ATORVASTATIN ACID; ATORVASTATIN LACTONE; DRUG METABOLITE; FIMASARTAN; ORGANIC ANION TRANSPORTER 2; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NONHUMAN; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URTICARIA; XENOPUS LAEVIS;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AREA UNDER CURVE; BIPHENYL COMPOUNDS; CROSS-OVER STUDIES; DRUG INTERACTIONS; ESTRONE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; OOCYTES; ORGANIC ANION TRANSPORTERS; PYRIMIDINES; PYRROLES; RNA, COMPLEMENTARY; TETRAZOLES; XENOPUS LAEVIS; YOUNG ADULT;

EID: 80955135088     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31822b9092     Document Type: Article

References (41)

1. Yi S, Kim TE, Yoon SH, et al. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. J Cardiovasc Pharmacol. 2011;57:682-689.
2. Boryung Pharmaceutical Co. Ltd, May 2010. The clinical study to evaluate the efficacy and safety of fimasartan in patients with mild to moderate essential hypertension [Clinical Trials.gov web site]. Available at: http:// www.clinicaltrials.gov/ct2/show/NCT01135212?term=fimasartan&rank=6. Accessed November 3, 2010.
3. Lane A, Engmann MB, Bryson S, et al. Single dose pharmacokinetics (PK) and pharmacodynamics (PD) of BR-A-657, an angiotensin II (AII) antagonist. Clin Pharmacol Ther. 2005;77:P59.
4. Lane A, Kleinermanns D, Bryson S, et al. Multiple dose pharmacokinetics (PK) and pharmacodynamics (PD) of BR-A-657, an angiotensin II (AII) antagonist. Clin Pharmacol Ther. 2005;77:P58.
5. Yi S, Kim JW, Kim TE, et al. Effect of multiple doses of fimasartan, an angiotensin II receptor antagonist, on the steady-state pharmacokinetics of digoxin in healthy volunteers. Int J Clin Pharmacol Ther. 2011;49: 321-327.
6. A service of the U.S. National Institutes of Health [ClinicalTrials.gov website]. Available at: http://clinicaltrials.gov/ct2/show/NCT01289886?term= NCT01289886&rank=1. Accessed April 3, 2011.
7. A service of the U.S. National Institutes of Health [ClinicalTrials.gov web site]. Available at: http://clinicaltrials.gov/ct2/show/NCT01289899?term= NCT01289899&rank=1. Accessed April 3, 2011.
8. Lau YY, Huang Y, Frassetto L, et al. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007;81:194-204.
9. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 2003;42:1141-1160.
10. Jacobsen W, Kuhn B, Soldner A, et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000;28:1369-1378.
11. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006; 112:71-105.
12. Werner N, Nickenig G, Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol. 2002;97:105-116.
13. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000;13:3S-10S.
14. Sander GE, Giles TD. Hypertension and lipids: lipid factors in the hypertension syndrome. Curr Hypertens Rep. 2002;4:458-463.
15. Nickenig G. Should angiotensin II receptor blockers and statins be combined? Circulation. 2004;110:1013-1020.
16. Heerey A, Barry M, Ryan M, et al. The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci. 2000;169:176-179.
17. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipidlowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80:565-581.
18. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother. 2001;35:1096-1107.
19. Chatzizisis YS, Koskinas KC, Misirli G, et al. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf. 2010;33: 171-187.
20. Jung TR, Hwang SW, Lee JU, et al. Comparative consistency between obesity determination standards using body mass index and ideal body weight. J Korean Acad Fam Med. 2001;22:1765-1771.
21. Shen W, Punyanitya M, Chen J, et al. Waist circumference correlates with metabolic syndrome indicators better than percentage fat. Obesity (Silver Spring). 2006;14:727-736.
22. Jemal M, Ouyang Z, Chen BC, et al. Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom. 1999;13: 1003-1015.
23. Hermann M, Christensen H, Reubsaet JL. Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS. Anal Bioanal Chem. 2005;382:1242-1249.
24. Kouzuki H, Suzuki H, Ito K, et al. Contribution of organic anion transporting polypeptide to uptake of its possible substrates into rat hepatocytes. J Pharmacol Exp Ther. 1999;288:627-634.
25. Deng JW, Shon JH, Shin HJ, et al. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin. Pharm Res. 2008;25:1807-1814.
26. Smith CC, Bernstein LI, Davis RB, et al. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med. 2003;163:688-692.
27. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137:581-585.
28. Chatzizisis YS, Misirli G, Hatzitolios AI, et al. The syndrome of rhabdomyolysis: complications and treatment. Eur J Intern Med. 2008;19: 568-574.
29. Fukazawa I, Uchida N, Uchida E, et al. Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. Br J Clin Pharmacol. 2004;57:448-455.
30. Backman JT, Luurila H, Neuvonen M, et al. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther. 2005;78:154-167.
31. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther. 1998;64:58-65.
32. Lee MG. Evaluation of Fimasartan as Potential Substrate for ABC and SLC Transporter System. Department of Pharmacology, Yonsei University College of Medicine; 2009.
33. Kalliokoski A, Backman JT, Kurkinen KJ, et al. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin Pharmacol Ther. 2008;84:488-496.
34. U.S. Department of Health and Human Services, FDA, drug interaction studies-study design, data analysis, and implications for dosing and labelling [FDA web site] Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/ucm072101.pdf. Accessed November 1, 2010.
35. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos. 2003;31:815-832.
36. Zamuner S, Johnson BM, Pagliarusco S, et al. Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine. Br J Clin Pharmacol. 2010;70:537-546.
37. Yamashiro W, Maeda K, Hirouchi M, et al. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos. 2006; 34:1247-1254.
38. Yamada A, Maeda K, Kamiyama E, et al. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007;35:2166-2176.
39. Ishiguro N, Maeda K, Kishimoto W, et al. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos. 2006;34:1109-1115.
40. Yasar U, Sain-Guven G, Yardimci Y, et al. Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients. Basic Clin Pharmacol Toxicol. 2011;109:73-77.
41. Frishman WH, Horn J. Statin-drug interactions: not a class effect. Cardiol Rev. 2008;16:205-212.